25 completed, 6 terminated, 5 unknown, 3 active not recruiting. 43 Phase 2, 6 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 25, Terminated 6, Unknown 5, Active not recruiting 3, Recruiting 3, Not yet recruiting 1 |
| Phase 1 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
Follow University of Ulm: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Olympion Medical Center | 32 | 2027-01-01 | 2025-05-25 |
| Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia Venetoclax; Rituximab, DRC - Waldenstrom Macroglobulinemia, Treatment Naive | Phase 2 | Recruiting | Christian Buske | 80 | 2025-03-21 | 2026-05-05 |
| Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease Prednisolone, Placebo - Osteoporosis Secondary | Phase 2 | Completed | Odense University Hospital | 36 | 2024-11-04 | 2026-10-20 |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] KEYTRUDA® - Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Leipzig | 140 | 2024-04-17 | 2024-09-20 |
| Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoadsorption, Immunoglobulins - CIDP | Phase 2 | Recruiting | University of Ulm | 20 | 2023-05-01 | 2026-05-01 |
| Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY Rituximab, Pembrolizumab - Marginal Zone Lymphoma | Phase 2 | Terminated | University of Ulm | 22 | 2022-03-01 | 2026-02-27 |
| Copanlisib and Rituximab in Marginal Zone Lymphoma Patients Copanlisib, Rituximab - Marginal Zone Lymphoma | Phase 2 | Active not recruiting | Christian Buske | 36 | 2019-12-15 | 2026-05-06 |
| Starting the Conversation STC - Stigma of Parents of Children With Mental Illness | Phase 2 | Terminated | University of Ulm | 5 | 2019-10-01 | 2021-05-07 |
| Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia Ibrutinib / Bortezomib / Rituximab - Waldenstrom Macroglobulinemia | Phase 2 | Active not recruiting | Christian Buske | 53 | 2019-09-11 | 2025-12-05 |
| To Share Or Not To Share 2Share - History of Suicide Attempt | Phase 2 | Terminated | University of Ulm | 4 | 2019-05-07 | 2020-03-13 |
| Obinutuzumab in Marginal Zone Lymphoma Obinutuzumab - Marginal Zone Lymphoma | Phase 2 | Active not recruiting | Christian Buske | 56 | 2018-11-23 | 2026-05-06 |
| Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 Vosaroxin, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) | Phase 2 | Completed | University of Ulm | 9 | 2018-04-19 | 2020-10-28 |
| Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis Pharyngeal Electrical Stimulation - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Completed | University of Ulm | 20 | 2018-02-01 | 2021-03-08 |
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma Temozolomide, Aprepitant, Minocycline - Glioblastoma | Phase 1 / Phase 2 | Completed | University of Ulm | 10 | 2016-11-01 | 2021-10-05 |
| A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis Injection (2x106 ASC/5ml)., Injection (10x106 ASC/5ml)., Placebo - Osteoarthritis | Phase 2 | Completed | University Hospital, Montpellier | 100 | 2016-09-20 | 2026-06-12 |
| Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL ibrutinib, obinutuzumab, venetoclax - Leukemia, Lymphocytic, Chronic | Phase 2 | Completed | University of Ulm | 41 | 2016-09-01 | 2023-01-17 |
| Honest Open Proud for Adolescents With Mental Illness Honest Open Proud (HOP) - Secrecy Versus Disclosure Among Adolescents With Mental Illness | Phase 2 | Completed | University of Ulm | 100 | 2016-05-01 | 2017-05-09 |
| Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Volasertib, Cytarabine, Daunorubicin - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | University of Ulm | 6 | 2016-02-01 | 2018-02-28 |
| Study of Palbociclib in MLL-rearranged Acute Leukemias Palbociclib - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | University of Ulm | 50 | 2015-07-01 | 2019-04-16 |
| PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer Aflibercept - Metastatic Colorectal Cancer | Phase 2 | Unknown | University of Ulm | 150 | 2015-03-01 | 2019-09-20 |
Showing 20 of 43. Sign in to see all of them.
Leukemia, Myeloid, Acute (8) · Neoplasms (4) · Amyotrophic Lateral Sclerosis (3) · Coronary Artery Disease (3) · Glioblastoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Social Stigma (3) · Colorectal Neoplasms (2) · Mental Disorders (2) · Waldenstrom Macroglobulinemia (2) · Acute Kidney Injury (1) · Chromosome 17 deletion (1) · Cystic Fibrosis (1) · Disease (1)
Cytarabine (7) · Daunorubicin (4) · Rituximab (4) · Etoposide (3) · Idarubicin (3) · Azacitidine (2) · Disulfiram (2) · Mitoxantrone (2) · Temozolomide (2) · ibrutinib (2) · obinutuzumab (2) · pembrolizumab (2) · venetoclax (2) · Alemtuzumab (1) · Amitriptyline (1)
Germany (39) · Austria (8) · Greece (3) · France (2) · Denmark (1) · United States (1)
Christian Buske, MD (3) · Christian Buske, Prof. Dr. (2) · Hartmut Doehner, MD (2) · Thomas Seufferlein, Prof. Dr. (2) · Albert C Ludolph, MD, Prof. (1) · Albert C. Ludolph, MD, Prof. (1) · Anja Lisbeth Frederiksen, MD (1) · Arnold Ganser, Prof. Dr. (1) · Christian Jorgensen, MD, PhD (1) · Claus Bogh Juhl, MD (1) · Frieder Keller, M.D. (1) · Joachim Riethmueller, Dr (1)
PMID 19059939, PMID 19602710, PMID 20421455, PMID 21199047, PMID 21242187, PMID 21343560, PMID 21372155, PMID 21670448, PMID 22715372, PMID 22965967, PMID 24335498, PMID 24344045, PMID 25270908, PMID 26479969, PMID 26772812, PMID 27036160, PMID 27696203, PMID 27774990, PMID 29063805, PMID 29205343, PMID 29466429, PMID 29507629, PMID 29720733, PMID 29934198, PMID 30563875, PMID 31467127, PMID 32223334, PMID 33884617, PMID 34187401, PMID 34620071, PMID 34959641, PMID 35154390, PMID 35213393, PMID 35486475, PMID 37348018, PMID 37885041, PMID 38396172, PMID 38620092, PMID 38875244, PMID 39239277, PMID 40433816, PMID 40550489, PMID 40885690, PMID 41039315
2017 (2), 2008 (1), 2009 (1), 2014 (1), 2023 (1)